Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.
Journal Article (Clinical Trial;Journal Article)
The objective was to examine duloxetine 60-120 mg/day treatment for relapse prevention in adults with generalized anxiety disorder (GAD). Adult patients (N=887; mean age=43.3 years; 61.0% female) with DSM-IV-TR-defined GAD diagnosis were treated with duloxetine for 26 weeks. Patients who completed open-label phase and were treatment responders (>or=50% reduction in Hamilton Anxiety Rating Scale total score to or=2-point increase in illness severity ratings or by discontinuation due to lack of efficacy. During the double-blind phase, placebo-treated patients (N=201) relapsed more frequently (41.8%) than duloxetine-treated patients (13.7%, N=204, P
Full Text
Duke Authors
Cited Authors
- Davidson, JRT; Wittchen, H-U; Llorca, P-M; Erickson, J; Detke, M; Ball, SG; Russell, JM
Published Date
- September 2008
Published In
Volume / Issue
- 18 / 9
Start / End Page
- 673 - 681
PubMed ID
- 18559291
International Standard Serial Number (ISSN)
- 0924-977X
Digital Object Identifier (DOI)
- 10.1016/j.euroneuro.2008.05.002
Language
- eng
Conference Location
- Netherlands